Bevacizumab may cause you to develop a hole in the wall of your stomach or intestine. This is a serious and possibly life-threatening condition. If you experience any of the following symptoms, call your doctor immediately: stomach pain, constipation, nausea, vomiting, shivering, or fever.
Bevacizumab may slow the healing of wounds, such as cuts made by a doctor during surgery. In some cases, bevacizumab may cause a wound that has closed to split open. This is a serious and possibly life-threatening condition. If you experience this problem, call your doctor immediately. Tell your doctor if you have recently had surgery or if you plan to have surgery. If you have recently had surgery, you should not use bevacizumab until at least 28 days have passed and until the area has completed healed. If you are scheduled to have surgery, your doctor will stop your treatment with bevacizumab at least 28 days before the surgery.
Bevacizumab may cause severe bleeding that can be life-threatening. Tell your doctor if you have recently coughed up blood. If you experience any of the following symptoms at any time during your treatment, call your doctor immediately: nosebleeds or bleeding from your gums, coughing up or vomiting blood or material that looks like coffee grounds, unusual bleeding or bruising, increased menstrual flow or vaginal bleeding, pink, red, or dark brown urine, red or tarry black bowel movements, headache, dizziness, or weakness.
Talk to your doctor about the risks of using bevacizumab.
Bevacizumab is used with chemotherapy to treat cancer of the colon (large intestine) or rectum that has spread to other parts of the body. Bevacizumab is also used with chemotherapy to treat certain types of lung cancer. Bevacizumab is also used to treat glioblastoma (a certain type of cancerous brain tumor) that has not improved or has come back after treatment with other medications. Bevacizumab is also used in combination with another medication to treat renal cell cancer (RCC, a type of cancer that begins in the kidney) that has spread to other parts of the body. Bevacizumab is also used with chemotherapy to treat cervical cancer (cancer that begins in the opening of the uterus [womb]) and certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer that has not improved or has come back after treatment with other medications. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors.
Bevacizumab comes as a solution to administer slowly into a vein. Bevacizumab is administered by a doctor or nurse in a medical office, infusion center, or hospital. Bevacizumab is usually given once every 2 or 3 weeks.
It should take 90 minutes for you to receive your first dose of bevacizumab. A doctor or nurse will watch you closely to see how your body reacts to bevacizumab. If you do not have any serious problems when you receive your first dose of bevacizumab, it will usually take 30 to 60 minutes for you to receive each of your remaining doses of the medication.
Bevacizumab injection may cause serious reactions during infusion of the medication. If you experience any of the following symptoms, tell your doctor immediately: difficulty breathing or shortness of breath, chills, shaking, sweating, headaches, chest pain, dizziness, feeling faint, flushing, itching, rash, or hives. Your doctor may need to slow down your infusion, or delay or stop your treatment if you experience these or other side effects.
Bevacizumab has previously been used to treat breast cancer, however, further investigation by the FDA has found that the risks associated with treatment do not justify use for the benefit found in most cases. Bevacizumab is also sometimes used to treat wet age-related macular degeneration (AMD; an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities). Talk to your doctor about the risks of using bevacizumab to treat your condition.
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
Before receiving bevacizumab,
Unless your doctor tells you otherwise, continue your normal diet.
If you miss an appointment to receive a dose of bevacizumab, call your doctor as soon as possible.
Bevacizumab may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately:
Bevacizumab may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online ( Web Site ) or by phone (1-800-332-1088).
In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at Web Site. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
Keep all appointments with your doctor. Your doctor will check your blood pressure and test your urine regularly during your treatment with bevacizumab.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
AHFS® Consumer Medication Information. © Copyright, The American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.
Selected Revisions: July 15, 2018.